John Naus
Psychiatry · Colleyville, TXNPI 1932328291
Payments from drug & device makers
Across 839 payments — averaging $195.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$52K
- Supernus Pharmaceuticals, Inc.$29K
- Teva Pharmaceuticals USA, Inc.$26K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$24K
- E.r. Squibb & Sons, L.L.C.$17K
- Sunovion Pharmaceuticals Inc.$8K
- plus $7K from 29 others
What the payments were for
- Consulting fees$5,5003%
- Speaking & faculty fees$132,35981%
- Travel & lodging$11,9637%
- Food & beverage$13,8308%
- Education$5400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$34,441
- QELBREE$27,896
- CAPLYTA$23,094
- ABILIFY MYCITE$16,328
- Austedo XR$14,401
- COBENFY$13,752
- AUSTEDO$10,125
- LATUDA$8,041
- Equetro$270
- Auvelity$103
How this compares
$164,192 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 22 | $8,448 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 146 | $5,096 |
| Lisdexamfetamine Dimesylate | 24 | $4,306 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 72 | $3,413 |
| Clonazepam | 114 | $1,015 |
| Diazepam | 81 | $982 |
| Temazepam | 52 | $853 |
| Alprazolam | 155 | $750 |
| Quetiapine Fumarate | 36 | $749 |
| Bupropion Hcl SrBupropion Hcl | 28 | $619 |
| Methylphenidate Hcl | 21 | $585 |
| Zolpidem Tartrate | 69 | $569 |
| Zolpidem Tartrate ErZolpidem Tartrate | 24 | $511 |
| Lorazepam | 72 | $419 |
| Trazodone Hcl | 39 | $376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $481 | $8,44822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Colleyville
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.